Moontomas commented on a stock · Aug 30, 2023 11:13

SHPH NEWS Revolutionizing Antitumor Immune Responses: HDAC6 Inhibition

On August 29, 2023, Shuttle Pharmaceuticals Holdings, Inc. has published a groundbreaking manuscript revealing the potential of their innovative selective HDAC6 inhibitor, SP-2-225, to enhance antitumor immune responses and inhibit tumor growth.

This combination therapy with radiation therapy holds immense promise in the fight against cancer, and could revolutionize the field of oncology.

Cmon let's send it!

SOURCE LINK:Revolutionizing Antitumor Immune Responses The Promise of HDAC6 Inhibition

HDAC6 Inhibition

PERSONAL OPINION;NOT ADVICE

$AMC Entertainment(AMC.US)$ $Xiao-I(AIXI.US)$

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

8982 Views

Comment

Moontomas

🐋 Swing play Short Squeeze Based on my own TA&DD. NOT ADVICE

196Followers

163Following

1358Visitors